INS and Hyperinsulinemia: Thus, our results indicated that saroglitazar (2 and 4 mg/kg/day, PO) treatment improved insulin sensitivity in adipose tissue, and decreased hyperglycemia and hyperinsulinemia in MSG-obese Wistar rats.